Oncology News

BOSTON — Resolution of metabolic dysfunction-associated steatohepatitis without worsening of fibrosis was linked to long-term survival after bariatric surgery, similar to that of patients without baseline MASH, according to a presenter.

Postdiagnosis antidepressant use reduced mortality risk among patients with hepatocellular carcinoma, according to data published in JAMA Network Open.

Rates of hepatocellular carcinoma caused by alcohol-related disease and nonalcoholic fatty liver disease are on the rise, especially among Hispanic individuals, according to research in Clinical Gastroenterology and Hepatology.

Type 2 diabetes was an independent predictor of hepatic decompensation and development of hepatocellular carcinoma among patients with nonalcoholic fatty liver disease, according to data.

Proteins and genetic material secreted by fatty liver cells stimulate the spread of colorectal cancer to the liver, study results published in Cell Metabolism showed.

Research demonstrated that hepatocellular carcinoma surveillance is cost-effective at a lower incidence threshold of 0.7% in virologically cured patients with hepatitis C virus, underscoring the need to update clinical guidelines.

Failure to achieve sustained virological response and the presence of more advanced chronic liver disease were associated with mortality in patients with hepatitis C and hepatocellular carcinoma, according to a researcher at EASL Congress.

The combination of durvalumab and tremelimumab-actl conferred a sustained OS benefit at 4 years among patients with unresectable hepatocellular carcinoma, according to phase 3 trial results from the agents’ manufacturer.

Scoring systems based on behavioral and clinical data outperformed existing scores in predicting risk for hepatocellular carcinoma in patients with chronic hepatitis B virus infection, according to data presented at the EASL Congress.

Healio will present its sixth annual Disruptive Innovators Awards for gastroenterology and hepatology this fall.